Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Cash from Financing Activities (2021 - 2025)

Historic Cash from Financing Activities for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Q3 2025 value amounting to $191.6 million.

  • Amylyx Pharmaceuticals' Cash from Financing Activities rose 23940750.0% to $191.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $257.3 million, marking a year-over-year increase of 5488867.52%. This contributed to the annual value of $348000.0 for FY2024, which is 9017.78% down from last year.
  • Latest data reveals that Amylyx Pharmaceuticals reported Cash from Financing Activities of $191.6 million as of Q3 2025, which was up 23940750.0% from -$31000.0 recorded in Q2 2025.
  • In the past 5 years, Amylyx Pharmaceuticals' Cash from Financing Activities ranged from a high of $232.2 million in Q4 2022 and a low of -$1.1 million during Q4 2021
  • Over the past 5 years, Amylyx Pharmaceuticals' median Cash from Financing Activities value was $964500.0 (recorded in 2023), while the average stood at $47.3 million.
  • Examining YoY changes over the last 5 years, Amylyx Pharmaceuticals' Cash from Financing Activities showed a top increase of 23940750.0% in 2025 and a maximum decrease of 21481.48% in 2025.
  • Quarter analysis of 5 years shows Amylyx Pharmaceuticals' Cash from Financing Activities stood at -$1.1 million in 2021, then surged by 21899.25% to $232.2 million in 2022, then plummeted by 99.9% to $230000.0 in 2023, then crashed by 52.17% to $110000.0 in 2024, then soared by 174087.27% to $191.6 million in 2025.
  • Its Cash from Financing Activities stands at $191.6 million for Q3 2025, versus -$31000.0 for Q2 2025 and $65.7 million for Q1 2025.